Free Trial
NASDAQ:CVAC

CureVac (CVAC) Stock Price, News & Analysis

CureVac logo
$5.44 -0.02 (-0.37%)
Closing price 04:00 PM Eastern
Extended Trading
$5.43 -0.01 (-0.18%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About CureVac Stock (NASDAQ:CVAC)

Key Stats

Today's Range
$5.44
$5.46
50-Day Range
$4.07
$5.60
52-Week Range
$2.37
$5.72
Volume
259,109 shs
Average Volume
788,872 shs
Market Capitalization
$1.22 billion
P/E Ratio
5.91
Dividend Yield
N/A
Price Target
$6.83
Consensus Rating
Hold

Company Overview

CureVac Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
89th Percentile Overall Score

CVAC MarketRank™: 

CureVac scored higher than 89% of companies evaluated by MarketBeat, and ranked 112th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CureVac has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    CureVac has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about CureVac's stock forecast and price target.
  • Earnings Growth

    Earnings for CureVac are expected to decrease in the coming year, from $0.72 to ($0.39) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CureVac is 5.91, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.88.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CureVac is 5.91, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.75.

  • Price to Book Value per Share Ratio

    CureVac has a P/B Ratio of 1.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about CureVac's valuation and earnings.
  • Percentage of Shares Shorted

    1.11% of the float of CureVac has been sold short.
  • Short Interest Ratio / Days to Cover

    CureVac has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CureVac has recently increased by 18.95%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    CureVac does not currently pay a dividend.

  • Dividend Growth

    CureVac does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.11% of the float of CureVac has been sold short.
  • Short Interest Ratio / Days to Cover

    CureVac has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CureVac has recently increased by 18.95%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    CureVac has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for CureVac this week, compared to 3 articles on an average week.
  • MarketBeat Follows

    2 people have added CureVac to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CureVac insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.15% of the stock of CureVac is held by insiders.

  • Percentage Held by Institutions

    Only 17.26% of the stock of CureVac is held by institutions.

  • Read more about CureVac's insider trading history.
Receive CVAC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CureVac and its competitors with MarketBeat's FREE daily newsletter.

CVAC Stock News Headlines

Take a look at this picture ...
A strange investment secret — discovered just a few short weeks before this image was taken — correctly predicted it all. Even crazier, this secret accurately called every major financial event in recent history … Now it's signaling something very scary is about to hit the market again …
UBS Downgrades CureVac N.V. (CVAC)
See More Headlines

CVAC Stock Analysis - Frequently Asked Questions

CureVac's stock was trading at $3.41 on January 1st, 2025. Since then, CVAC shares have increased by 59.5% and is now trading at $5.44.

CureVac N.V. (NASDAQ:CVAC) posted its earnings results on Thursday, May, 22nd. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.08. The business had revenue of $0.94 million for the quarter, compared to analyst estimates of $4.27 million. CureVac had a trailing twelve-month return on equity of 30.89% and a net margin of 35.44%.

CureVac (CVAC) raised $200 million in an IPO on Friday, August 14th 2020. The company issued 13,300,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and Credit Suisse acted as the underwriters for the IPO and Berenberg and Kempen were co-managers.

CureVac's top institutional investors include Alpine Associates Management Inc. (0.88%), Quinn Opportunity Partners LLC (0.12%), Geode Capital Management LLC (0.11%) and Forsta AP Fonden (0.07%).

Shares of CVAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CureVac investors own include NVIDIA (NVDA), PayPal (PYPL), Tesla (TSLA), NIO (NIO), Advanced Micro Devices (AMD), Meta Platforms (META) and Moderna (MRNA).

Company Calendar

Last Earnings
5/22/2025
Today
8/08/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CVAC
CIK
1809122
Employees
880
Year Founded
N/A

Price Target and Rating

High Price Target
$10.00
Low Price Target
$5.00
Potential Upside/Downside
+25.6%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.92
Trailing P/E Ratio
5.91
Forward P/E Ratio
7.56
P/E Growth
N/A
Net Income
$175.50 million
Net Margins
35.44%
Pretax Margin
39.67%
Return on Equity
30.89%
Return on Assets
25.54%

Debt

Debt-to-Equity Ratio
0.05
Current Ratio
7.65
Quick Ratio
7.64

Sales & Book Value

Annual Sales
$579.18 million
Price / Sales
2.11
Cash Flow
$0.87 per share
Price / Cash Flow
6.24
Book Value
$3.36 per share
Price / Book
1.62

Miscellaneous

Outstanding Shares
224,340,000
Free Float
219,515,000
Market Cap
$1.22 billion
Optionable
Optionable
Beta
2.53

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:CVAC) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners